NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.71 -0.11 (-3.90 %)
(As of 12/9/2018 04:00 PM ET)
Previous Close$2.71
Today's Range$2.70 - $2.8350
52-Week Range$2.56 - $4.71
Volume1.94 million shs
Average Volume1.89 million shs
Market Capitalization$451.59 million
P/E Ratio-4.37
Dividend YieldN/A
Beta1.32
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
Previous Symbol
CUSIP76655960
Phone650-624-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio6.15
Quick Ratio6.12

Price-To-Earnings

Trailing P/E Ratio-4.37
Forward P/E Ratio-6.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.48 million
Price / Sales100.80
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.69 per share
Price / Book3.93

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-77,990,000.00
Net MarginsN/A
Return on Equity-97.75%
Return on Assets-82.59%

Miscellaneous

Employees103
Outstanding Shares166,640,000
Market Cap$451.59 million
OptionableOptionable

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. The biotechnology company had revenue of $4.87 million for the quarter, compared to analysts' expectations of $3.52 million. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

7 analysts have issued 12 month price targets for Rigel Pharmaceuticals' shares. Their predictions range from $7.00 to $10.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $8.2143 in the next year. This suggests a possible upside of 203.1% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

What is the consensus analysts' recommendation for Rigel Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (11/30/2018)
  • 2. Cantor Fitzgerald analysts commented, "We believe Rigel is poised to achieved meaningful commercial sales of TAVALISSE in immune thrombocytopenia. In addition to ITP, we see expansion opportunities in AIHA and IgAN. Valuation Summary We arrive at our 12-month price target of $9/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from fostamatinib for immune-related disorders." (10/3/2018)
  • 3. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $7.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from Tavalisse without any current contribution from pipeline assets. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2018)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

Media stories about RIGL stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 57)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 59)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Thomas A. Raffin, Co-Founder (Age 71)

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (8.19%), Vanguard Group Inc. (4.45%), Sofinnova Ventures Inc (1.96%), Morgan Stanley (1.63%) and Candriam Luxembourg S.C.A. (1.36%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Eldon C Mayer III, Nelson Cabatuan, Raul R Rodriguez and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Which institutional investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Credit Suisse AG, Bank of New York Mellon Corp and TIAA CREF Investment Management LLC. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Nelson Cabatuan. View Insider Buying and Selling for Rigel Pharmaceuticals.

Which institutional investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Sofinnova Ventures Inc, Fuller & Thaler Asset Management Inc., Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Sio Capital Management LLC, FMR LLC and BlackRock Inc.. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.71.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $451.59 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is http://www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel